Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Sep;91(9):3349-54.
doi: 10.1210/jc.2005-2226. Epub 2006 Apr 11.

Thiazolidinedione use and bone loss in older diabetic adults

Ann V Schwartz  1 , Deborah E Sellmeyer, Eric Vittinghoff, Lisa Palermo, Beata Lecka-Czernik, Kenneth R Feingold, Elsa S Strotmeyer, Helaine E Resnick, Laura Carbone, Brock A Beamer, Seok Won Park, Nancy E Lane, Tamara B Harris, Steven R Cummings
Affiliations

Thiazolidinedione use and bone loss in older diabetic adults

Ann V Schwartz et al. J Clin Endocrinol Metab. 2006 Sep.

Abstract

Context: Activation of peroxisome proliferator-activated receptor-gamma by thiazolidinediones (TZDs) results in lower bone mass in mice.

Objective: The objective of the study was to determine whether TZD use is associated with changes in bone mineral density (BMD) in older adults with type 2 diabetes.

Design: We analyzed 4-yr follow-up data from the Health, Aging, and Body Composition observational study.

Setting: The study was conducted in a general community.

Patients: White and black, physically able men and women, aged 70-79 yr at baseline with diabetes defined by self-report, use of hypoglycemic medication, elevated fasting glucose (>/=126 mg/dl), or elevated 2-h glucose tolerance test (>/=200 mg/dl) participated in the study.

Main outcome measures: Whole-body, lumbar spine (derived from whole body), and hip BMD were measured by dual-energy x-ray absorptiometry at 2-yr intervals.

Results: Of 666 diabetic participants, 69 reported TZD use at an annual visit, including troglitazone (n = 22), pioglitazone (n = 30), and/or rosiglitazone (n = 31). Those with TZD use had higher baseline hemoglobin A(1c) and less weight loss over 4 yr but similar baseline BMD and weight than others with diabetes. In repeated-measures models adjusted for potential confounders associated with TZD use and BMD, each year of TZD use was associated with greater bone loss at the whole body [additional loss of -0.61% per year; 95% confidence interval (CI) -1.02, -0.21% per year], lumbar spine (-1.23% per year; 95% CI -2.06, -0.40% per year), and trochanter (-0.65% per year; 95% CI -1.18, -0.12% per year) in women, but not men, with diabetes.

Conclusion: These observational results suggest that TZDs may cause bone loss in older women. These results need to be tested in a randomized trial.

PubMed Disclaimer

Comment in

References

    1. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351:1106–18. - PubMed
    1. Einhorn D, Aroda VR, Henry RR. Glitazones and the management of insulin resistance: what they do and how might they be used. Endocrinol Metab Clin North Am. 2004;33:595, vii–616. - PubMed
    1. Wysowski DK, Armstrong G, Governale L. Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001. Diabetes Care. 2003;26:1852–5. - PubMed
    1. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology. 2004;145:401–6. - PMC - PubMed
    1. Soroceanu MA, Miao D, Bai XY, Su H, Goltzman D, Karaplis AC. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol. 2004;183:203–16. - PubMed

Publication types

MeSH terms